[1] Wechalekar AD, Gillmore JD, Hawkins PN.  Systemic amyloidosis[J]. Lancet, 2016, 387(10038): 2641-2654.   doi: 10.1016/S0140-6736(15)01274-X
[2] Gertz MA.  Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment[J]. Am J Hematol, 2016, 91(9): 947-956.   doi: 10.1002/ajh.24433
[3]

Xu JH, Wang MJ, Shen Y, et al. Effects of amyloid light-chain amyloidosis on clinical characteristics and prognosis in multiple myeloma: a single-center retrospective study[J/OL]. Cancer Manag Res, 2021, 13: 1343−1356[2023-08-31]. https://www.dovepress.com/effects-of-amyloid-light-chain-amyloidosis-on-clinical-characteristics-peer-reviewed-fulltext-article-CMAR. DOI: 10.2147/CMAR.S287922.
[4]

Khalil G, Fiani D, Antaki F, et al. Primary gastric amyloidosis associated with linitis plastica and delayed progression to systemic amyloidosis and multiple myeloma[J/OL]. BMJ Case Rep, 2023, 16(5): e252786[2023-08-31]. https://casereports.bmj.com/content/16/5/e252786.long. DOI: 10.1136/bcr-2022-252786.
[5] Falk RH, Alexander KM, Liao R, et al.  AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy[J]. J Am Coll Cardiol, 2016, 68(12): 1323-1341.   doi: 10.1016/j.jacc.2016.06.053
[6] Fuchida SI, Kawamura K, Sunami K, et al.  Retrospective analysis of autologous stem cell transplantation for AL amyloidosis: a study from the multiple myeloma working group of the japan society for hematopoietic cell transplantation[J]. Transplant Cell Ther, 2022, 28(2): 76-82.   doi: 10.1016/j.jtct.2021.10.021
[7] Di Nunzio D, Recupero A, De Gregorio C, et al.  Echocardiographic findings in cardiac amyloidosis: inside two-dimensional, Doppler, and strain imaging[J]. Curr Cardiol Rep, 2019, 21(2): 7-.   doi: 10.1007/s11886-019-1094-z
[8] Manwani R, Page J, Lane T, et al.  A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement[J]. Amyloid, 2018, 25(4): 247-252.   doi: 10.1080/13506129.2018.1552852
[9] Law WP, Wang WYS, Moore PT, et al.  Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study[J]. J Nucl Med, 2016, 57(11): 1733-1739.   doi: 10.2967/jnumed.115.169870
[10] Seo M, Cha HJ, Kim M, et al.  Clinical utility of 18F-florbetaben PET for detecting amyloidosis associated with multiple myeloma: a prospective case-control study[J]. Clin Nucl Med, 2019, 44(9): e503-e509.   doi: 10.1097/RLU.0000000000002699
[11]

Griffin JM, Rosenthal JL, Grodin JL, et al. ATTR amyloidosis: current and emerging management strategies: JACC: CardioOncology state-of-the-art review[J/OL]. JACC CardioOncol, 2021, 3(4): 488−505[2023-08-31]. https://www.sciencedirect.com/science/article/pii/S2666087321001551?via%3Dihub. DOI: 10.1016/j.jaccao.2021.06.006.
[12] Xie BQ, Wang JX, Xi XY, et al.  Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging[J]. Eur J Nucl Med Mol Imaging, 2022, 49(8): 2786-2797.   doi: 10.1007/s00259-021-05674-9
[13] Guo W, Chen HJ.  68Ga FAPI PET/MRI in cardiac amyloidosis[J]. Radiology, 2022, 303(1): 51-.   doi: 10.1148/radiol.211951
[14] Xi XY, Wang L, Liu AJ, et al.  Myocardial fibroblast activation imaging in light chain cardiac amyloidosis[J]. J Nucl Cardiol, 2023, 30(4): 1690-1692.   doi: 10.1007/s12350-022-02963-0
[15] Wang XZ, Guo YB, Gao YJ, et al.  Feasibility of 68Ga-labeled fibroblast activation protein inhibitor PET/CT in light-chain cardiac amyloidosis[J]. JACC Cardiovasc Imaging, 2022, 15(11): 1960-1970.   doi: 10.1016/j.jcmg.2022.06.004
[16] Cook J, Muchtar E, Warsame R.  Updates in the diagnosis and management of AL amyloidosis[J]. Curr Hematol Malig Rep, 2020, 15(3): 155-167.   doi: 10.1007/s11899-020-00574-5
[17] Greipp PR, San Miguel J, Durie BGM, et al.  International staging system for multiple myeloma[J]. J Clin Oncol, 2005, 23(15): 3412-3420.   doi: 10.1200/JCO.2005.04.242
[18] Vaxman I, Gertz M.  Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis[J]. Acta Haematol, 2019, 141(2): 93-106.   doi: 10.1159/000495455
[19]

Imdad U. Amyloidosis of the heart: a comprehensive review[J/OL]. Cureus, 2023, 5(2): e35264[2023-08-31]. https://www.cureus.com/articles/40909-amyloidosis-of-the-heart-a-comprehensive-review#!. DOI: 10.7759/cureus.35264.
[20] Kim D, Choi JO, Kim K, et al.  Untangling amyloidosis: recent advances in cardiac amyloidosis[J]. Int J Heart Fail, 2020, 2(4): 231-239.   doi: 10.36628/ijhf.2020.0016
[21] Mishra S, Guan J, Plovie E, et al.  Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish[J]. Am J Physiol Heart Circ Physiol, 2013, 305(1): H95-H103.   doi: 10.1152/ajpheart.00186.2013
[22] Palumbo A, Anderson K.  Multiple myeloma[J]. N Engl J Med, 2011, 364(11): 1046-1060.   doi: 10.1056/NEJMra1011442
[23] Tovar N, Rodríguez-Lobato LG, Cibeira MT, et al.  Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome[J]. Amyloid, 2018, 25(2): 79-85.   doi: 10.1080/13506129.2018.1443439
[24] Kyle RA, Larson DR, Kurtin PJ, et al.  Incidence of AL amyloidosis in Olmsted county, minnesota, 1990 through 2015[J]. Mayo Clin Proc, 2019, 94(3): 465-471.   doi: 10.1016/j.mayocp.2018.08.041